Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from LLY

The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

Barchart

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

Barchart

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Members of Congress Bought These 5 Stocks—Should You?

Five stocks recently traded by members of Congress—from AI defense to GLP-1 leaders—could offer clues for investors building their watchlists

MarketBeat

3 Stocks That Could Be Next to Announce a Stock Split

Stock splits often follow strong growth. Here are three high-priced stocks that could be candidates for a stock split in 2026

MarketBeat

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

MarketBeat

The Real Reason Eli Lilly Is Pouring $3 Billion Into China

Eli Lilly's major investment in China's manufacturing capacity is a strategic move to secure its supply chain and capture a vast, untapped growth market.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years

Discover three megatrend stocks positioned for the next decade of growth as AI, healthcare innovation, and clean energy reshape the global economy

MarketBeat

Is Moderna Stock Outperforming the Dow?

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Viking Therapeutics: The High-Stakes Weight Loss Contender

Viking Therapeutics is positioning itself as a contender in the obesity market with a dual strategy of rapid clinical progress and commercial preparation.

MarketBeat

Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

Barchart

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Barchart

Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

MarketBeat

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

Barchart

What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

MarketBeat

This NVIDIA Partnership Shows How Big AI Can Really Get

NVIDIA is well-positioned to dominate AI markets across industries and verticals for years to come; analysts point to a 40% upside.

MarketBeat

MarketBeat Week in Review – 12/29 - 01/02

Stocks staged a rally on the first day of trading in 2026, which aligns with the general sense that the markets will grind higher, despite valuation concerns

MarketBeat

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large potential catalysts on the horizon.

MarketBeat

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

Benzinga

Healthcare Relevancies Clashes With Premium Valuations For Direxion's LLY-Focused ELIL, ELIS ETFs

In terms of sheer relevance, it's difficult to think of a more relevant sector than healthcare — and within this vast ecosystem, only an elite few occupy the same neighborhood as pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In November 2025, Eli Lilly became the first trillion-dollar pharmaceutical company, mostly…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.